Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies.

MLA

Mostafa, Mohamed E. A., and Tariq Alrasheed. “Risk of Bone Fracture by Using Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis of Population-Based Cohort Studies.” Frontiers in Endocrinology, vol. 15, Oct. 2024, p. 1410883. EBSCOhost, https://doi.org/10.3389/fendo.2024.1410883.

APA

Mostafa, M. E. A., & Alrasheed, T. (2024). Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies. Frontiers in Endocrinology, 15, 1410883. https://doi.org/10.3389/fendo.2024.1410883

Chicago

Mostafa, Mohamed E A, and Tariq Alrasheed. 2024. “Risk of Bone Fracture by Using Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, or Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis of Population-Based Cohort Studies.” Frontiers in Endocrinology 15 (October): 1410883. doi:10.3389/fendo.2024.1410883.